Chromosome-packing blockers for bacterial eye infections
Chromosome Packing Inhibitors for the Treatment of Eye Infections
This project explores a new type of antibiotic that blocks how bacteria pack their DNA to help people with bacterial eye infections, such as those after surgery or from contact lenses.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma NIH-funded |
| Lab location | 1 site (Norman, United States) |
| Project ID | NIH-11171393 on NIH RePORTER |
What this research studies
Researchers are developing drugs called condensin inhibitors that disrupt how bacteria organize their chromosomes, which is important for their ability to cause disease. They will study how blocking condensins changes the way Pseudomonas aeruginosa interacts with the eye and host defenses. The team will test a lead condensin inhibitor in a live model of bacterial keratitis to see if it can reduce infection and damage. The goal is to find a new antibiotic mechanism that could work against drug-resistant eye infections and protect vision.
Who could benefit from this research
Good fit: People with bacterial eye infections, especially bacterial keratitis after eye surgery or contact lens use, would be the likely candidates for future clinical testing of this approach.
Not a fit: Patients with viral, fungal, allergic, or other non-bacterial eye conditions would not be expected to benefit from this bacterial-targeted therapy.
Why it matters
Potential benefit: If successful, this could lead to a new antibiotic option that works against resistant bacteria and helps prevent vision loss from bacterial eye infections.
How similar studies have performed: This approach is largely novel — targeting bacterial condensins is a new mechanism that has not yet been tested in human eye infections, though other novel antibiotics have sometimes helped resistant infections.
Where this research is happening
Norman, United States
- University of Oklahoma — Norman, United States (Active)
Researchers
- Principal investigator: Rybenkov, Valentin V — University of Oklahoma
- Study coordinator: Rybenkov, Valentin V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.